Company History
|
BioE is a biomedical company whose mission is to commercialize human umbilical cord blood stem cells and the associated tools and technologies needed to develop life-enhancing therapeutics and pharmaceuticals via high-quality cellular research and drug discovery. BioE was founded in 1993. Since 2001, our strategic focus has been on the commercialization of the company's proprietary Multi-Lineage Progenitor Cell™ (MLPC™) stem cell lines, and our innovative PrepaCyte® technology for the processing of cord blood stem cells and other therapeutically important cells. BioE is organized into two business areas surrounding these platform technologies in an effort to facilitate research partnerships and product commercialization. In 2004, we discovered the MLPC using our PrepaCyte platform. This very early-stage stem cell is comparable to an embryonic stem cell in its ability to differentiate into many common cell and tissue types — including neural stem cells, nerve cells, lung cells, early stage liver and pancreas cells, skeletal muscle, fat cells, bone cells and blood vessels. Based on its origin and differentiation capabilities, the MLPC represents and defines a new category of stem cell that bridges the limitations of a bone marrow-derived stem cell and the safety and ethical concerns of an embryonic stem cell. In July 2005, BioE became the first company in the world to commercialize this type of stem cell — licensing the MLPC to academia and industry for research, regenerative medicine and drug development. Looking ahead, the MLPC may be developed for a variety of therapeutic uses in humans. BioE's PrepaCyte platform was used to develop our PrepaCyte-CB Processing System, which is designed specifically for cord blood processing. A multi-site in vitro clinical study sponsored by BioE evaluated and confirmed PrepaCyte-CB's performance for processing of cord blood to maximize nucleated cell recovery including stem cells. BioE received FDA 510(k) clearance for its PrepaCyte-CB Cord Blood Processing System in December 2008.
|